Загрузка...
Sorafenib exerts anti-glioma activity in vitro and in vivo
Despite conventional treatment strategies glioblastoma, the most common malignant primary brain has a bad prognosis with median survival times of 12-15 month. In this study, the efficacy of sorafenib (Nexavar, BAY43-9006), a multikinase inhibitor, on glioblastoma cells was evaluated both in vitro an...
Сохранить в:
| Главные авторы: | , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2010
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3198851/ https://ncbi.nlm.nih.gov/pubmed/20470863 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.neulet.2010.05.009 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|